Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
PVLA 
Palvella Therapeutics, Inc (PVLA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/31/2025: PVLA (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $81.23
1 Year Target Price $81.23
| 7 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 118.37% | Avg. Invested days 41 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 10/31/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 883.00M USD | Price to earnings Ratio - | 1Y Target Price 81.23 |
Price to earnings Ratio - | 1Y Target Price 81.23 | ||
Volume (30-day avg) 9 | Beta - | 52 Weeks Range 11.17 - 80.79 | Updated Date 11/2/2025 |
52 Weeks Range 11.17 - 80.79 | Updated Date 11/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.53 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -37.25% | Return on Equity (TTM) -151.15% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 622233818 | Price to Sales(TTM) - |
Enterprise Value 622233818 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 11059665 | Shares Floating 6381758 |
Shares Outstanding 11059665 | Shares Floating 6381758 | ||
Percent Insiders 22.86 | Percent Institutions 56.3 |
Upturn AI SWOT
Palvella Therapeutics, Inc
Company Overview
History and Background
Palvella Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for serious, rare genetic diseases with no approved treatments. Founded to address unmet medical needs, they are primarily focused on dermatologic conditions.
Core Business Areas
- Drug Development: Focuses on research and development of new therapies for rare skin diseases, particularly those with genetic causes.
Leadership and Structure
Information about Palvella's leadership team and organizational structure is not readily available in public sources.
Top Products and Market Share
Key Offerings
- QTORINu2122 (recifercept): A topical formulation being developed for the treatment of pachyonychia congenita (PC). As it's an investigational drug without approval, there is no revenue, number of users, or market share data. Competitors developing potential therapies for PC are rare, reflecting the niche nature of the indication. These could include companies exploring gene therapies or other novel approaches.
Market Dynamics
Industry Overview
The industry is the biopharmaceutical sector, specifically focusing on rare genetic diseases. It is characterized by high risk, high reward, with significant regulatory hurdles.
Positioning
Palvella is positioned as a specialist in rare genetic skin diseases, focusing on areas with high unmet medical need. Their competitive advantage lies in their focus on a specific niche.
Total Addressable Market (TAM)
The TAM for pachyonychia congenita is relatively small due to the rarity of the condition. Exact TAM figures are difficult to obtain but is likely in the tens to hundreds of millions, depending on pricing and market penetration. Palvella's positioning is to capture a significant share of this niche market if QTORINu2122 is approved.
Upturn SWOT Analysis
Strengths
- Specialized focus on rare genetic skin diseases
- Potential first-in-class therapy for pachyonychia congenita
- Strong intellectual property position
Weaknesses
- Reliance on a single product candidate
- Limited financial resources compared to larger pharmaceutical companies
- Regulatory approval risk
Opportunities
- Expansion to other rare genetic skin diseases
- Partnerships with larger pharmaceutical companies
- Orphan drug designation and potential market exclusivity
Threats
- Clinical trial failures
- Regulatory delays or rejection
- Competition from other emerging therapies
Competitors and Market Share
Key Competitors
Competitive Landscape
Without any publicly traded company focused exclusively on PC, direct market share comparison is not applicable. However, if approved, Palvella would have a significant competitive advantage being first-in-class.
Growth Trajectory and Initiatives
Historical Growth: Not applicable as a private company with limited public information.
Future Projections: Future growth depends heavily on the successful development and commercialization of QTORINu2122 and potential expansion into other indications. Analyst estimates are unavailable.
Recent Initiatives: Focus on clinical development of QTORINu2122 and preparation for potential regulatory submissions.
Summary
Palvella Therapeutics is a biopharmaceutical company specializing in rare genetic skin diseases, with a lead product candidate, QTORINu2122, targeting pachyonychia congenita. The company's success hinges on the positive outcome of clinical trials and regulatory approvals. While focusing on a niche market provides opportunities, the company faces risks associated with single-asset dependency and competition from emerging therapies. Palvella needs to succeed with QTORIN, or find a partnership, to create a stable revenue stream.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Palvella Therapeutics website
- ClinicalTrials.gov
- Industry reports on rare disease therapeutics
Disclaimers:
This analysis is based on limited publicly available information and should not be considered financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Palvella Therapeutics, Inc
Exchange NASDAQ | Headquaters Wayne, PA, United States | ||
IPO Launch date 2024-12-16 | Founder, President, CEO & Director Mr. Wesley H. Kaupinen | ||
Sector Healthcare | Industry Biotechnology | Full time employees 14 | Website https://palvellatx.com |
Full time employees 14 | Website https://palvellatx.com | ||
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN 3.9% rapamycin anhydrous gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.